What is Lifeward's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for Lifeward year over year?

What does Lifeward do and what are its main business segments?

What were the key takeaways from Lifeward's earnings call?

What is the market's earnings forecast for Lifeward next quarter?

What guidance did Lifeward's management provide for the next earnings period?

What factors drove the changes in Lifeward's revenue and profit?

What were the key takeaways from Lifeward’s earnings call?

**Key Takeaways:**
- **Revenue Growth**: Q3 revenue up 8% QoQ, driven by Medicare ReWalk sales, with 2025 guidance reaffirmed at $24-26M.
- **Margin Expansion**: Gross margin improved to 43.7%, operating loss down 27% YoY, signaling efficiency gains.
- **European Expansion**: CE-marked ReWalk 7 targets 40% of global exoskeleton market, with 33 active German rentals.
- **Financial Resilience**: $3M loan bolsters liquidity, with cash to fund operations into Q1 2026.
- **Strategic Shifts**: Sales force restructuring and channel partnerships aim to unlock AlterG growth and neuro rehab market share.

**【CEO Summary Section】**
- **Operational Transformation**: CEO Mark Grant highlights a 16% reduction in quarterly cash burn and 27% decline in non-GAAP operating loss YoY, driven by streamlined operations and cost efficiencies.
- **Market Expansion**: Secured first Medicare Advantage revenue for ReWalk 7 and expanded into Europe with CE mark approval, targeting 40% of global exoskeleton opportunity.
- **Financial Strength**: Completed a $3M loan with Oramed, enhancing liquidity and supporting transformation efforts.

**【CFO Financial Commentary】**
- **Revenue Performance**: Q3 2025 revenue $6.2M (+1.1% YoY, +8% QoQ), with ReWalk product line contributing $2.9M (50% from Medicare).
- **Profitability**: Gross margin improved to 43.7% (vs. 36.2% YoY), driven by lower production costs post-manufacturing consolidation.
- **Efficiency Gains**: Non-GAAP operating expenses down 15% YoY to $5.7M, reflecting reduced R&D spend and streamlined marketing/sales.
- **Liquidity**: $2M cash post-loan, supporting operations into Q1 2026.

**【Q&A Highlights】**
- **ReWalk Momentum**: 15 units delivered Q3 vs. 4 YoY, with 117 U.S. leads and 33 Germany rentals (3-6mo conversion rate).
- **AlterG Strategy**: Restructured sales teams to focus on capital sales and neuro rehab, aiming to stabilize and grow AlterG revenue.
- **Guidance Confidence**: Q4 typically strongest quarter; $24-26M 2025 guidance supported by backlog and pipeline strength.
- **Partnership Impact**: CorLife collaboration growing pipeline, with 20+ beta programs underway.
- **Global Ambitions**: Eyeing 40% European market share, with CE-marked ReWalk 7 targeting worker's comp and broader rehab use cases.

Lifeward Ltd. (LFWD) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

LFWD

LFWD fundamentals

You can ask Aime